Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ConvaTec Group Plc (CNVVF)
Reading, GB
ConvaTec Group Plc is a global medical technology company focused on creating, producing, and distributing a wide array of healthcare products. Their offerings span several key areas: Advanced Wound Management: This includes specialized dressings and skincare solutions for treating both acute and chronic wounds, which can arise from conditions like diabetes, prolonged immobility, venous disease, traumatic injuries, burns, or surgical interventions. Ostomy Care: The company provides vital devices, accessories, and support services for individuals who have undergone ostomy procedures, often necessitated by conditions such as colorectal or bladder cancer, inflammatory bowel disease, or obesity. Continence and Critical Care: This division offers intermittent urinary catheters and related products to help manage urinary continence issues for patients with spinal cord injuries, multiple sclerosis, spina bifida, and other urological conditions. It also supplies a range of devices crucial for intensive care units and broader hospital settings. Specialized Monitoring and Management Systems: ConvaTec develops advanced systems for managing acute fecal incontinence, meticulously monitoring urine output, and assessing intra-abdominal pressure. Disposable Medical Supplies: Their portfolio includes a variety of single-use medical items such as wound drainage systems, urine collection bags and catheters, equipment for airway management and oxygen therapy, suction apparatus, gastroenterology tubes, and securement devices. Infusion Technology: They also manufacture disposable infusion sets for insulin pumps used in diabetes care, as well as for other continuous infusion treatments. ConvaTec distributes its products globally to a diverse clientele, including pharmacies, hospitals, and various acute and post-acute healthcare providers, either directly or via a network of distributors and wholesalers. Their customer base encompasses healthcare professionals, patients, and other manufacturers. Founded in 1978, ConvaTec Group Plc is headquartered in Reading, United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +11.28% | -12.54% | -23.09% | -15.65% | -10.75% | -12.83% | -6.61% | -19.54% | -18.28% | -18.28% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Instruments & Supplies: +7.9%+8.9% ★ Q4'25: +14.7% (vs Q4'23)
-
EPS growth Medical - Instruments & Supplies: +16.3%-5.1% Q4'25: -4.6% (vs Q4'23)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+13.9% Q4'25: +19.5% (vs Q4'23)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+16.7% ★ Q4'25: +17.7% (vs Q4'23)
-
ROIC Medical - Instruments & Supplies: +6.0%+10.4% ★ Q4'25: +22.3% (vs Q4'23)
-
Share dilution Medical - Instruments & Supplies: +0.1%-1.1% ★ Q4'25: -2.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×2.50× Q4'25: 1.19× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 17 Rev. Ana. 1 EPS Ana. |
Dec 2027 17 Rev. Ana. 1 EPS Ana. |
Dec 2028 9 Rev. Ana. 1 EPS Ana. |
Dec 2029 14 Rev. Ana. 1 EPS Ana. |
Dec 2030 8 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.55B
est: 1.70B (-8.8%)
|
1.85B
est: 1.74B (+6.3%)
|
1.75B
est: 1.84B (-4.8%)
|
1.83B
est: 1.82B (+0.2%)
|
1.89B
est: 1.89B (+0.4%)
|
2.04B
est: 2.03B (+0.3%)
|
2.07B
est: 2.06B (+0.7%)
|
2.14B
est: 2.14B (+0.3%)
|
2.29B
est: 2.29B (0.0%)
|
2.49B
est: 2.43B (+2.7%)
|
2.57B
2.52B – 2.61B
+5.8% YoY
|
2.74B
2.67B – 2.81B
+6.7% YoY
|
2.91B
2.85B – 2.97B
+6.3% YoY
|
3.14B
3.07B – 3.20B
+7.7% YoY
|
3.41B
3.33B – 3.47B
+8.5% YoY
|
| EBITDA |
271.16M
est: 371.90M (-27.1%)
|
423.84M
est: 382.62M (+10.8%)
|
440.80M
est: 403.35M (+9.3%)
|
321.49M
est: 400.05M (-19.6%)
|
448.67M
est: 413.77M (+8.4%)
|
395.52M
est: 445.69M (-11.3%)
|
450.50M
est: 451.59M (-0.2%)
|
455.50M
est: 468.54M (-2.8%)
|
540.20M
est: 512.41M (+5.4%)
|
645.03M
est: 543.35M (+18.7%)
|
575.05M
564.47M – 583.10M
+5.8% YoY
|
613.75M
597.29M – 628.27M
+6.7% YoY
|
652.16M
637.32M – 664.54M
+6.3% YoY
|
702.36M
686.38M – 715.69M
+7.7% YoY
|
762.29M
744.95M – 776.76M
+8.5% YoY
|
| EBIT |
108.60M
est: 199.45M (-45.5%)
|
222.40M
est: 205.19M (+8.4%)
|
259.32M
est: 216.31M (+19.9%)
|
103.63M
est: 214.54M (-51.7%)
|
237.92M
est: 221.90M (+7.2%)
|
187.50M
est: 239.02M (-21.6%)
|
245.10M
est: 242.18M (+1.2%)
|
240.70M
est: 251.27M (-4.2%)
|
319.40M
est: 288.33M (+10.8%)
|
416.05M
est: 305.74M (+36.1%)
|
323.58M
317.63M – 328.11M
+5.8% YoY
|
345.36M
336.09M – 353.53M
+6.7% YoY
|
366.97M
358.62M – 373.93M
+6.3% YoY
|
395.22M
386.22M – 402.72M
+7.7% YoY
|
428.94M
419.18M – 437.08M
+8.5% YoY
|
| Net Income |
-185.72M
est: 195.89M (-194.8%)
|
158.40M
est: 318.89M (-50.3%)
|
221.60M
est: 329.54M (-32.8%)
|
9.80M
est: 260.08M (-96.2%)
|
112.50M
est: 244.53M (-54.0%)
|
117.60M
est: 263.50M (-55.4%)
|
62.90M
est: 257.92M (-75.6%)
|
130.30M
est: 269.23M (-51.6%)
|
190.50M
est: 303.45M (-37.2%)
|
178.89M
est: 361.74M (-50.5%)
|
403.36M
391.44M – 413.31M
+11.5% YoY
|
460.01M
446.40M – 471.36M
+14.0% YoY
|
512.54M
497.38M – 525.19M
+11.4% YoY
|
575.01M
558.00M – 589.21M
+12.2% YoY
|
661.14M
641.59M – 677.46M
+15.0% YoY
|
| SGA |
675.20M
est: 651.53M (+3.6%)
|
637.30M
est: 670.30M (-4.9%)
|
656.20M
est: 706.61M (-7.1%)
|
699.40M
est: 700.84M (-0.2%)
|
725.40M
est: 724.87M (+0.1%)
|
825.00M
est: 780.79M (+5.7%)
|
790.80M
est: 791.13M (0.0%)
|
825.40M
est: 820.83M (+0.6%)
|
840.20M
est: 859.86M (-2.3%)
|
844.37M
est: 911.78M (-7.4%)
|
964.98M
947.22M – 978.48M
+5.8% YoY
|
1.03B
1.00B – 1.05B
+6.7% YoY
|
1.09B
1.07B – 1.12B
+6.3% YoY
|
1.18B
1.15B – 1.20B
+7.7% YoY
|
1.28B
1.25B – 1.30B
+8.5% YoY
|
| EPS |
-0.10
est: 0.10 (-201.3%)
|
0.09
est: 0.16 (-45.0%)
|
0.11
est: 0.16 (-31.3%)
|
0.01
est: 0.13 (-95.9%)
|
0.06
est: 0.12 (-52.5%)
|
0.06
est: 0.13 (-54.3%)
|
0.03
est: 0.13 (-75.2%)
|
0.06
est: 0.13 (-51.2%)
|
0.09
est: 0.15 (-37.7%)
|
0.09
est: 0.18 (-50.3%)
|
0.20
0.19 – 0.20
+11.5% YoY
|
0.23
0.22 – 0.23
+14.0% YoY
|
0.25
0.24 – 0.26
+11.4% YoY
|
0.28
0.27 – 0.29
+12.2% YoY
|
0.33
0.32 – 0.33
+15.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-21 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jonathan Mason | Chief Executive Officer & Director | 3M | male |
| Fiona Victoria Ryder | Group Financial Controller, Chief Financial Officer & Director | 948.2K | female |
| David Shepherd | Chief Commercial Officer | — | male |
| Divakar Ramakrishnan | Chief Science, Innovation & Quality Officer | — | — |
| Emma Rose | EVP & Chief People Officer | — | female |
| Evelyn Douglas | EVP and Chief Strategy & Business Development Officer | — | female |
| James Edward Spencer Kerton | EVP, General Counsel & Company Secretary | — | male |
| Kjersti Grimsrud Biotechnology | President & Chief Operating Officer of Infusion Care | — | female |
| Anne Belcher | President & Chief Operating Officer of Global Emerging Markets | — | female |
| Walter Morse | Interim Chief Quality & Operations Officer | — | male |
| Bruno Pinheiro | President & Chief Operating Officer of Ostomy Care | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CNVVF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
